HemaSphere (Jun 2022)

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]

  • A. Vannucchi,
  • R. Mesa,
  • A. Gerds,
  • H. K. Al-Ali,
  • D. Lavie,
  • A. Kuykendall,
  • S. Grosicki,
  • A. Iurlo,
  • Y. T. Goh,
  • M. Lazaroiu,
  • M. Egyed,
  • M. L. Fox,
  • D. McLornan,
  • A. Perkins,
  • S.-S. Yoon,
  • V. Gupta,
  • J.-J. Kiladjian,
  • R. Donahue,
  • J. Kawashima,
  • S. Verstovsek

DOI
https://doi.org/10.1097/01.HS9.0000847068.32650.9b
Journal volume & issue
Vol. 6
pp. 940 – 941

Abstract

Read online

No abstracts available.